These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 17002160

  • 1. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG.
    Lakartidningen; ; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract] [Full Text] [Related]

  • 2. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
    Schatz H.
    Dtsch Med Wochenschr; 2005 Aug 05; 130(31-32):1825-30. PubMed ID: 16052448
    [No Abstract] [Full Text] [Related]

  • 3. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
    Szymborska-Kajanek A, Strojek K.
    Kardiol Pol; 2006 Mar 05; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
    [No Abstract] [Full Text] [Related]

  • 4. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ.
    Diabet Med; 2006 Feb 05; 23(2):109-12. PubMed ID: 16433706
    [No Abstract] [Full Text] [Related]

  • 5. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P, Attvall S, Nilsson PM.
    Lakartidningen; 2006 Feb 05; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract] [Full Text] [Related]

  • 6. Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
    Karalliedde J, Viberti GC.
    Diabetes; 2007 May 05; 56(5):e3; author reply e4. PubMed ID: 17470560
    [No Abstract] [Full Text] [Related]

  • 7. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ.
    Am J Ther; 2007 May 05; 14(1):49-62. PubMed ID: 17303976
    [Abstract] [Full Text] [Related]

  • 8. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E.
    MMW Fortschr Med; 2005 Oct 13; 147(41):6. PubMed ID: 16270501
    [No Abstract] [Full Text] [Related]

  • 9. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM.
    Am J Cardiol; 2008 Dec 22; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract] [Full Text] [Related]

  • 10. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
    Sacks FM.
    Am J Cardiol; 2008 Dec 22; 102(12A):34L-40L. PubMed ID: 19084088
    [Abstract] [Full Text] [Related]

  • 11. What to make of ACCORD. Surprising new results from the landmark diabetes study.
    Johns Hopkins Med Lett Health After 50; 2010 Sep 22; 22(7):1-2, 7. PubMed ID: 20848750
    [No Abstract] [Full Text] [Related]

  • 12. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF, Lohray BB.
    J Clin Pharmacol; 2008 Aug 22; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract] [Full Text] [Related]

  • 13. Therapy and clinical trials.
    Usman M, Peter R.
    Curr Opin Lipidol; 2006 Oct 22; 17(5):612-4. PubMed ID: 16960511
    [No Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.
    Metabolism; 2007 Oct 22; 56(10):1396-401. PubMed ID: 17884451
    [Abstract] [Full Text] [Related]

  • 15. [Type 2 diabetes: is the treatment based on evidence?].
    Boussageon R.
    Rev Med Suisse; 2010 Sep 01; 6(260):1624-5; author reply 1625. PubMed ID: 20853719
    [No Abstract] [Full Text] [Related]

  • 16. [Too positive comment on glitazones].
    Lindberg M.
    Ugeskr Laeger; 2007 Feb 19; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract] [Full Text] [Related]

  • 17. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
    MMW Fortschr Med; 2008 Aug 28; 150(32-35):56-7. PubMed ID: 19009700
    [No Abstract] [Full Text] [Related]

  • 18. Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
    Taskinen MR.
    Nutr Metab Cardiovasc Dis; 2006 Dec 28; 16(8):509-12. PubMed ID: 17071064
    [No Abstract] [Full Text] [Related]

  • 19. [World news in age-related diabetes: blood sugar lowering can improve prognosis].
    Einecke D.
    MMW Fortschr Med; 2005 Sep 22; 147(38):1. PubMed ID: 16218218
    [No Abstract] [Full Text] [Related]

  • 20. [Prospective pioglitazone clinical trial in macrovascular events].
    Asanuma H, Kitakaze M.
    Nihon Rinsho; 2012 May 22; 70 Suppl 3():301-8. PubMed ID: 22768537
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.